Submission of Matters to a Vote of Security Holders

Business Context and Reporting Period

This Form 8-K, dated December 20, 2023 and signed December 22, 2023, reports the results of Coeptis Therapeutics Holdings, Inc.’s annual meeting of stockholders held on December 20, 2023. The filing identifies the registrant as Coeptis Therapeutics Holdings, Inc., although the request metadata identifies Z Squared Inc.; this discrepancy should be verified.

Of 34,108,036 common shares outstanding as of the record date, 21,951,175 shares, or approximately 64.36%, were present or represented by proxy.

Financial and Capitalization Information

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.

The stockholders approved, for purposes of Nasdaq Marketplace Rule 5635(d), the issuance of common shares underlying warrants originally issued in June 2023 and October 2023. The filing does not state the number of shares that may ultimately be issued.

Material Changes Versus the Prior Comparable Period

This filing reports annual meeting voting results and does not present comparative-period financial information or identify operating changes versus a prior period.

Stockholders approved an amendment to the 2022 Equity Incentive Plan adding 5,000,000 shares available for issuance.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • Seven director nominees were elected.
  • Turner Stone & Company, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
  • Stockholders approved, on a non-binding advisory basis, the compensation of the named executive officers.
  • The filing contains no management guidance, operating outlook, risk discussion, contingencies, or unusual financial items.
  • The planned adjournment proposal was not presented because sufficient votes were received on the other proposals.

Key Facts for Investor Verification

  • Verify the registrant identity because the filing names Coeptis Therapeutics Holdings, Inc., while the request metadata names Z Squared Inc.
  • Review the definitive proxy statement filed November 17, 2023 for proposal details, warrant terms, and the implications of the approved 5,000,000-share equity plan increase.
  • Assess potential dilution from the approved warrant-related share issuance and additional equity incentive plan shares; the filing does not quantify total potential dilution.
  • Confirm the fiscal year-end financial results separately, as this Form 8-K contains no financial statements or liquidity information.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.